Industry Strength Score
11/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
FRACTYL HEALTH INC (GUTS) Stock Price & Overview
NASDAQ:GUTS • US35168W1036
Current stock price
0.6993 USD
+0.06 (+9.69%)
At close:
0.6899 USD
-0.01 (-1.34%)
After Hours:
The current stock price of GUTS is 0.6993 USD. Today GUTS is up by 9.69%. In the past month the price increased by 53.39%. In the past year, price decreased by -55.74%.
GUTS Key Statistics
52-Week Range0.3772 - 3.03
Current GUTS stock price positioned within its 52-week range.
1-Month Range0.4256 - 0.7059
Current GUTS stock price positioned within its 1-month range.
- Market Cap
- 110.944M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.84
- Dividend Yield
- N/A
GUTS Stock Performance
Today
+9.69%
1 Week
+12.79%
1 Month
+53.39%
3 Months
+52.02%
Longer-term
6 Months -43.15%
1 Year -55.74%
2 Years -89.62%
3 Years N/A
5 Years N/A
10 Years N/A
GUTS Stock Chart
GUTS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GUTS. When comparing the yearly performance of all stocks, GUTS is a bad performer in the overall market: 71.64% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
GUTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GUTS. Both the profitability and financial health of GUTS have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GUTS Earnings
Next Earnings DateMay 19, 2026
Last Earnings DateMar 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.07
Revenue Reported
EPS Surprise 61.87%
Revenue Surprise %
GUTS Forecast & Estimates
11 analysts have analysed GUTS and the average price target is 5.34 USD. This implies a price increase of 664.31% is expected in the next year compared to the current price of 0.6993.
Analysts
Analysts83.64
Price Target5.34 (663.62%)
EPS Next Y62.3%
Revenue Next YearN/A
GUTS Index Membership
GUTS is currently included in the following stock indexes tracked on ChartMill.
GUTS Financial Highlights
Over the last trailing twelve months GUTS reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS decreased by -20.26% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-122.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.94% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%86.54%
Sales Q2Q%-100%
EPS 1Y (TTM)-20.26%
Revenue 1Y (TTM)N/A
GUTS Ownership
Ownership
Inst Owners72.9%
Shares158.65M
Float153.34M
Ins Owners1.32%
Short Float %2.54%
Short Ratio1.68
GUTS Industry Overview
GUTS operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
59/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
22%
Outperformed 22% of sub-industries
3 Month Rank
14%
Outperformed 14% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 14.2%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.3
- Average Fwd P/E
- 27.4
- Average Debt/Equity
- 0.5
GUTS Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.59B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 155.452B | ||
| SYK | STRYKER CORP | 17.41 | 112.876B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 83.969B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.418B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 45.068B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.515B | ||
| RMD | RESMED INC | 16.69 | 29.867B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 11.1 | 27.847B | ||
| DXCM | DEXCOM INC | 19.83 | 23.611B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.12 | 16.047B | ||
| PEN | PENUMBRA INC | 63.83 | 12.792B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.354B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GUTS
Company Profile
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Company Info
IPO: 2024-02-02
FRACTYL HEALTH INC
3 Van De Graaff Drive, Suite 200
Burlington MASSACHUSETTS US
Employees: 100
Phone: 17819028800
FRACTYL HEALTH INC / GUTS FAQ
What does GUTS do?
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
What is the current price of GUTS stock?
The current stock price of GUTS is 0.6993 USD. The price increased by 9.69% in the last trading session.
Does FRACTYL HEALTH INC pay dividends?
GUTS does not pay a dividend.
What is the ChartMill rating of FRACTYL HEALTH INC stock?
GUTS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about FRACTYL HEALTH INC (GUTS) stock?
11 analysts have analysed GUTS and the average price target is 5.34 USD. This implies a price increase of 664.31% is expected in the next year compared to the current price of 0.6993.
Would investing in FRACTYL HEALTH INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GUTS.
What is the employee count for GUTS stock?
FRACTYL HEALTH INC (GUTS) currently has 100 employees.